Page 60 - Lipids News Today

Chief among them was a reduction in cardiovascular mortality not observed in the pivotal trial that led to US approval of the drug.

A new Cholesterol Trialists Collaboration meta-analysis shows that in 14 of 15 people who experience muscle pain or weakness when taking a statin, symptoms are not related to treatment.

A new-generation causal-based AI algorithm promises to personalize CV risk management to prevent events.

Comprehensive cardiovascular screening fell short of significantly reducing all-cause mortality in men aged 65-74, but some benefits were seen in the whole group and for mortality in those younger than 70.

At ESC 2022, a palpable hush preceded the surprising results, which are likely to leave in place current guidelines for heart failure and revascularization.

The rise in digital platforms is opening more labor opportunities, but disparities remain with women who are getting less complex jobs and lower wages and those in the countryside facing challenges in access to fast  internet, according to a study by the Philippine Institute for Development Studies.

In a Medscape poll, physicians — even endocrinologists and cardiologists — said they dont have the time or the confidence in their knowledge to deliver nutrition counseling.

The new guidance addresses the role of nonstatin therapies for lowering LDL-C, which were not addressed in the 2018 ACC/AHA guideline on management of cholesterol.

The top 3 things you should know to start your day.

VAV Lipids, a biopharmaceuticals manufacturing company, headquartered in Mumbai, India has announced it will strengthen its presence by continuing to build a pipeline of COSMOS-certified ingredients